Nasdaq-listed Natus Medical to be taken private following ArchiMed deal

Natus, the US provider of medical device solutions to treat brain disorders and neural pathways, has agreed to be acquired by a subsidiary of Archimed, a French investment firm specialising in the healthcare sector. The deal is worth nearly $1.2bn.

Read the full article.